SBIR Phase I: Image-Guided Controlled Release Platform for Intratumoral Immunoadjuvant Del — NSF Award to ABSCO THERAPEUTICS, INC.
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is in developing an image-guided intratumoral therapy for treating immunotherapy-resistant solid tumors, a $125 billion market. The only FDA-approved intratumoral therapy costs $65,000–100,000 per patient and is in
| Award title | SBIR Phase I: Image-Guided Controlled Release Platform for Intratumoral Immunoadjuvant Del |
|---|---|
| Award ID | 2507269 |
| Awardee | ABSCO THERAPEUTICS, INC. |
| City | ALLSTON |
| State | MA |
| Amount obligated | $305,000 |
| Principal investigator | Stephen Linderman |
| Program | SBIR Phase I |
| Start date | 04/15/2025 |
| Abstract | The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is in developing an image-guided intratumoral therapy for treating immunotherapy-resistant solid tumors, a $125 billion market. The only FDA-approved intratumoral therapy costs $65,000–100,000 per patient and is insurance-reimbursed, demonstrating market viability. Pharmaceutical companies developing immune-oncology drugs are actively seeking strategic partnerships to improve drug delivery, |
| Source | NSF Awards |
$799/mo
Try NSFGrants →